Qiagen (QGEN) Earns “Buy” Rating from Deutsche Bank

Deutsche Bank reissued their buy rating on shares of Qiagen (NYSE:QGEN) in a report issued on Wednesday, May 8th, Borsen Zeitung reports.

A number of other research analysts also recently issued reports on QGEN. Zacks Investment Research downgraded Qiagen from a hold rating to a sell rating in a report on Tuesday, April 9th. Goldman Sachs Group restated a buy rating on shares of Qiagen in a research report on Tuesday, May 7th. Jefferies Financial Group restated a neutral rating on shares of Qiagen in a research report on Monday, January 14th. Finally, UBS Group initiated coverage on Qiagen in a research report on Friday, March 15th. They issued a neutral rating and a $42.00 price objective for the company. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Qiagen has a consensus rating of Buy and an average price target of $41.71.

Shares of NYSE:QGEN opened at $38.08 on Wednesday. Qiagen has a 12-month low of $32.33 and a 12-month high of $41.55. The company has a market capitalization of $8.52 billion, a price-to-earnings ratio of 28.42, a P/E/G ratio of 2.27 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The company had revenue of $348.70 million during the quarter, compared to the consensus estimate of $351.68 million. During the same period in the previous year, the company posted $0.26 earnings per share. Qiagen’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, sell-side analysts anticipate that Qiagen will post 1.43 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Lindbrook Capital LLC purchased a new stake in Qiagen in the 4th quarter valued at $25,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Qiagen in the 1st quarter valued at $30,000. Captrust Financial Advisors lifted its stake in shares of Qiagen by 165.3% in the 4th quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock valued at $35,000 after purchasing an additional 628 shares during the last quarter. Cornerstone Advisors Inc. acquired a new position in shares of Qiagen in the 1st quarter valued at $44,000. Finally, Bremer Trust National Association acquired a new position in shares of Qiagen in the 4th quarter valued at $45,000. Hedge funds and other institutional investors own 63.21% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Article: Technical Indicators – What is a Golden Cross?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.